These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39037185)

  • 1. Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R-LIVER).
    Schregel I; Papp M; Sipeki N; Kovats PJ; Taubert R; Engel B; Campos-Murguia A; Dalekos GN; Gatselis N; Zachou K; Milkiewicz P; Janik MK; Raszeja-Wyszomirska J; Ytting H; Braun F; Casar C; Sebode M; Lohse AW; Schramm C;
    Liver Int; 2024 Oct; 44(10):2687-2699. PubMed ID: 39037185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country.
    Choi J; Choi GH; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Kim KM
    Liver Int; 2019 May; 39(5):985-994. PubMed ID: 30821090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study.
    Plagiannakos CG; Hirschfield GM; Lytvyak E; Roberts SB; Ismail M; Gulamhusein AF; Selzner N; Qumosani KM; Worobetz L; Hercun J; Vincent C; Flemming JA; Swain MG; Cheung A; Chen T; Grbic D; Peltekain K; Mason AL; Montano-Loza AJ; Hansen BE;
    J Hepatol; 2024 Aug; 81(2):227-237. PubMed ID: 38527524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    Hartl J; Ehlken H; Sebode M; Peiseler M; Krech T; Zenouzi R; von Felden J; Weiler-Normann C; Schramm C; Lohse AW
    J Hepatol; 2018 Apr; 68(4):754-763. PubMed ID: 29180000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey.
    Joshita S; Yoshizawa K; Umemura T; Ohira H; Takahashi A; Harada K; Hiep NC; Tsuneyama K; Kage M; Nakano M; Kang JH; Koike K; Zeniya M; Yasunaka T; Takaki A; Torimura T; Abe M; Yokosuka O; Tanaka A; Takikawa H;
    J Gastroenterol; 2018 Sep; 53(9):1079-1088. PubMed ID: 29476251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes.
    Aljumah AA; Al-Ashgar H; Fallatah H; Albenmousa A
    Ann Hepatol; 2019; 18(3):439-444. PubMed ID: 31040094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worse fibro-inflammatory activity on diagnostic liver biopsy adversely impacts biochemical remission in autoimmune hepatitis.
    Khonde P; Choudhury S; Spies NC; Naz N; Stoll J; Fleckenstein J; He M; Ballentine S; Kulkarni S
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102442. PubMed ID: 39103121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis.
    Hartl J; Ehlken H; Weiler-Normann C; Sebode M; Kreuels B; Pannicke N; Zenouzi R; Glaubke C; Lohse AW; Schramm C
    J Hepatol; 2015 Mar; 62(3):642-6. PubMed ID: 25457202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis.
    Gerussi A; Halliday N; Saffioti F; Bernasconi DP; Roccarina D; Marshall A; Thorburn D
    Dig Liver Dis; 2020 Jul; 52(7):761-767. PubMed ID: 32473882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study.
    Ngu JH; Gearry RB; Frampton CM; Stedman CA
    Hepatology; 2013 Jun; 57(6):2399-406. PubMed ID: 23359353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, biochemical and histological features related to treatment response and prognosis in autoimmune hepatitis.
    Guedes LR; Cançado GGL; Santos BC; Jacomassi LDS; Nardelli MJ; Osório FMF; Faria LC; Couto CA
    Ann Hepatol; 2024; 29(4):101497. PubMed ID: 38460715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of poor response to therapy in Autoimmune Hepatitis.
    Muratori P; Lalanne C; Bianchi G; Lenzi M; Muratori L
    Dig Liver Dis; 2016 Sep; 48(9):1078-81. PubMed ID: 27378707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis.
    Hanouneh M; Ritchie MM; Ascha M; Ascha MS; Chedid A; Sanguankeo A; Zein NN; Hanouneh IA
    Scand J Gastroenterol; 2019 Jan; 54(1):76-80. PubMed ID: 30650311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands.
    van Gerven NM; Verwer BJ; Witte BI; van Erpecum KJ; van Buuren HR; Maijers I; Visscher AP; Verschuren EC; van Hoek B; Coenraad MJ; Beuers UH; de Man RA; Drenth JP; den Ouden JW; Verdonk RC; Koek GH; Brouwer JT; Guichelaar MM; Vrolijk JM; Mulder CJ; van Nieuwkerk CM; Bouma G;
    Scand J Gastroenterol; 2014 Oct; 49(10):1245-54. PubMed ID: 25123213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.
    Wang Q; Selmi C; Zhou X; Qiu D; Li Z; Miao Q; Chen X; Wang J; Krawitt EL; Gershwin ME; Han Y; Ma X
    J Autoimmun; 2013 Mar; 41():140-5. PubMed ID: 23187010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis.
    Miyake Y; Iwasaki Y; Terada R; Takagi S; Okamaoto R; Ikeda H; Sakai N; Makino Y; Kobashi H; Takaguchi K; Sakaguchi K; Shiratori Y
    J Hepatol; 2005 Dec; 43(6):951-7. PubMed ID: 16143423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis.
    Baven-Pronk MAMC; Biewenga M; van Silfhout JJ; van den Berg AP; van Buuren HR; Verwer BJ; van Nieuwkerk CMJ; Bouma G; van Hoek B
    Clin Transl Gastroenterol; 2018 Jul; 9(6):165. PubMed ID: 29961755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.
    Weber S; Benesic A; Rotter I; Gerbes AL
    Liver Int; 2019 Oct; 39(10):1906-1917. PubMed ID: 31319011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.